NBY - Wutah dodolan YoY (TTM) NovaBay Pharmaceuticals

Logo perusahaan publik NovaBay Pharmaceuticals Inc. (NBY)

The last twelve months (LTM) trading revenue growth rate reflects market expectations, where the value -74.80 captures this metric for NovaBay Pharmaceuticals (NBY). Growth is driven by Avenova synthesis automation and online distribution. The release of ophthalmology products based on approved pharmacy formulas ensures stability. In a saturated eye drop market, NovaBay Pharmaceuticals (NBY) is betting on physician loyalty and direct digital sales.

NBY (NovaBay Pharmaceuticals Inc.) riwayat Wutah dodolan YoY (TTM) saka 11.02.2024 nganti 18.04.2026

NovaBay Pharmaceuticals - rincian analitis lan metrik utama (NBY)

- rega saham lan target rega konsensus:
Analisis kabeh metrik perusahaan:novabay.com, NBY
Produk asil prodhuksi NovaBay

NovaBay Pharmaceuticals operational dynamics are reflected through the TTM annual revenue growth rate. This metric measures the change in the rolling annual sales volume, assessing the business expansion within the US market. The calculation is based on a comparison of the current twelve-month window with the same period from the previous year. For NovaBay Pharmaceuticals (NBY), this trend reveals the effectiveness of the struggle for market share amid pricing pressure from peers. Investors utilize this indicator to analyze sales resilience against marketing discounts.